The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Contacts
At |
At |
Julie Normart | |
(559) 974-3245 | (212) 915-2578 |
jnormart@w2ogroup.com | britchie@lifesciadvisors.com |
Source: Bellerophon Therapeutics, Inc.